This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013

NEW YORK (TheStreet) -- What a marvelous feeling to buy a stock and watch it rise in value.

I love checking my portfolio after I see a stock I own moving higher. Even more electrifying is when the stock is a dividend payer.

Historically, dividend stocks outperform non-dividend payers, but knowing which ones to buy is no easy task.

I spend a lot of time trying to help you avoid buying the dogs known as dividend traps. Dividend traps are the seemingly attractive high-yield, low-cost stocks that have a tendency to go even lower right after you buy them.

With careful research of sectors, costs in relation to earnings, technical analysis and spending time reading SEC filings, you can shift the odds.

Normally, I don't venture far from highly liquid names everyone knows. However, I'm finding other under-the-radar names that industry insiders know about, but the overall market doesn't. The potential gains are much greater if you're willing to sit and wait for others to discover the hidden value.

Of course, playing the waiting game isn't so tough when you're receiving checks in your mailbox every 90 days.

SLP Chart

First is a stock you may see often because I'm tremendously excited about its income-generating ability. This is not the first time I've highlighted Simulations Plus (SLP), and I doubt it will be my last. The company is a California-based, $100 million (market cap) software firm with massive gross and net margins. It's debt free, and it's small enough that most have never heard of it or the products outside of the pharmaceutical industry.

Customers love the cost savings from using the software compared to actual laboratory research. The top 20 pharmaceutical companies in the world are customers. Simulations Plus is a leader in the simulation software space that counts the FDA and MHRA (U.K's equivalent of the FDA) as clients.

The stock doesn't offer enough liquidity to trade it, but for long-term investors preferring dividends over daytrading, its 3.4% yield is hard to beat. I wrote a Real Money Pro post with exact entries and profit targets, and I bought this one myself.

SLP Revenue (Annual) Chart

From a cost of earnings perspective, the stock isn't expensive relative to its growth. The pharmaceutical space is in full merger mania, and I wouldn't be shocked if it spills over onto Simulations Plus. That said, the bull thesis doesn't require takeover speculation and I'm not betting on it.

Two analysts track Simulations Plus. Both share my opinion that the stock is a buy, but only one proffers a price target of $6.10.

During the last 12 months, the stock price has popped 52%.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
MO $57.75 0.43%
MRK $53.96 0.45%
PFE $32.79 -0.24%
AAPL $117.81 -0.19%
FB $105.45 0.04%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs